Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.57 |
| ▸ | S100A10 | P60903 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005956 | 0.88 | DRD4 (0.78) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4004582 | 0.87 | DRD4 (0.77) | DRD4DRD2ALDH1A1KDM4E | |
| SCHEMBL4005427 | 0.86 | DRD4 (0.78) | DRD4DRD2DRD3ALDH1A1ANXA2 | |
| SCHEMBL4004877 | 0.85 | DRD4 (0.76) | DRD4DRD2DRD3ALDH1A1ANXA2 | |
| SCHEMBL4002606 | 0.85 | DRD4 (0.76) | DRD4DRD2DRD3ALDH1A1ANXA2 | |
| SCHEMBL4003927 | 0.85 | DRD4 (0.73) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4008994 | 0.84 | DRD4 (0.74) | DRD4DRD2DRD3ALDH1A1ANXA2 | |
| SCHEMBL4003501 | 0.84 | ALDH1A1 (0.75) | DRD4DRD2DRD3ALDH1A1CYP1A2 | |
| SCHEMBL4005101 | 0.84 | DRD4 (1.00) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4007325 | 0.83 | DRD4 (0.71) | DRD4DRD2DRD3ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | claimed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | claimed |
| US-20190022091-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-10098875-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-16 | — | — | US | disclosed |
| US-9827242-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-9259423-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | Sumitomo Pharma Co., Ltd. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885DRD3 8/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | DRD4 1334/4885DRD2 1439/4885DRD3 1741/4885 |
| US-20190022091-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885DRD3 8/4885 |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885DRD3 8/4885 |
| US-10098875-B2 | Method of treatment for mental disorders | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885DRD3 8/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885DRD3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.